In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, C4 Therapeutics Inc’s stock clocked out at $2.26, down -8.87% from its previous closing price of $2.48. In other words, the price has decreased by -$8.87 from its previous closing price. On the day, 1.24 million shares were traded. CCCC stock price reached its highest trading level at $2.435 during the session, while it also had its lowest trading level at $2.25.
Ratios:
To gain a deeper understanding of CCCC’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.06 and its Current Ratio is at 5.06. In the meantime, Its Debt-to-Equity ratio is 0.36 whereas as Long-Term Debt/Eq ratio is at 0.33.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Barclays on September 17, 2025, initiated with a Overweight rating and assigned the stock a target price of $8.
On September 15, 2025, Stephens Upgraded its rating to Overweight which previously was Equal-Weight but kept the price unchanged to $6.
On September 04, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $8.Guggenheim initiated its Buy rating on September 04, 2025, with a $8 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 18 ’25 when Boyle Scott N sold 669 shares for $3.15 per share. The transaction valued at 2,107 led to the insider holds 107,805 shares of the business.
Boyle Scott N sold 490 shares of CCCC for $1,544 on Feb 14 ’25. The Chief Business Officer now owns 110,842 shares after completing the transaction at $3.15 per share. On Nov 18 ’24, another insider, Salter Malcolm, who serves as the Director of the company, bought 13,000 shares for $4.19 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CCCC now has a Market Capitalization of 210328736 and an Enterprise Value of 9215042. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.14 while its Price-to-Book (P/B) ratio in mrq is 0.92. Its current Enterprise Value per Revenue stands at 0.269 whereas that against EBITDA is -0.076.
Stock Price History:
The Beta on a monthly basis for CCCC is 2.89, which has changed by -0.5845896 over the last 52 weeks, in comparison to a change of 0.15566266 over the same period for the S&P500. Over the past 52 weeks, CCCC has reached a high of $6.52, while it has fallen to a 52-week low of $1.09. The 50-Day Moving Average of the stock is -10.62%, while the 200-Day Moving Average is calculated to be 2.83%.
Shares Statistics:
It appears that CCCC traded 2.05M shares on average per day over the past three months and 1705580 shares per day over the past ten days. A total of 71.01M shares are outstanding, with a floating share count of 66.52M. Insiders hold about 28.50% of the company’s shares, while institutions hold 60.32% stake in the company. Shares short for CCCC as of 1760486400 were 3987152 with a Short Ratio of 1.94, compared to 1757894400 on 3541042. Therefore, it implies a Short% of Shares Outstanding of 3987152 and a Short% of Float of 6.0500003.
Earnings Estimates
Currently, 4.0 analysts are dedicated to thoroughly evaluating and rating the performance of C4 Therapeutics Inc (CCCC) in the stock market.The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.31 and low estimates of -$0.43.
Analysts are recommending an EPS of between -$1.38 and -$1.57 for the fiscal current year, implying an average EPS of -$1.48. EPS for the following year is -$1.47, with 4.0 analysts recommending between -$1.18 and -$1.82.
Revenue Estimates
In. The current quarter, 5 analysts expect revenue to total $6.28M. It ranges from a high estimate of $8M to a low estimate of $5M. As of. The current estimate, C4 Therapeutics Inc’s year-ago sales were $15.36MFor the next quarter, 5 analysts are estimating revenue of $6.48M. There is a high estimate of $9.5M for the next quarter, whereas the lowest estimate is $3M.
A total of 5 analysts have provided revenue estimates for CCCC’s current fiscal year. The highest revenue estimate was $29.7M, while the lowest revenue estimate was $22M, resulting in an average revenue estimate of $26.5M. In the same quarter a year ago, actual revenue was $35.58M
